Research graph
References from Micro and nano-carriers-based pulmonary drug delivery system: Their current updates, challenges, and limitations – A review. Local targets link to admitted publications; unresolved targets remain external evidence.
Nanotherapeutics for pulmonary drug delivery: an emerging approach to overcome respiratory diseases
10.1016/j.jddst.2023.104261 · 2023 · External reference
Hydrogels for controlled pulmonary delivery
10.4155/tde.13.90 · 2013 · External reference
A hydrogel microparticle with sustained release properties for pulmonary drug delivery
10.1016/j.reactfunctpolym.2022.105489 · 2023 · External reference
Hyaluronic acid hydrogels for controlled pulmonary drug delivery—a particle engineering approach
10.3390/pharmaceutics13111878 · 2021 · External reference
Controlled drug delivery: historical perspective for the next generation
10.1016/j.jconrel.2015.10.005 · 2015 · External reference
Unresolved reference
2023 · External reference
Controlled drug delivery systems: past forward and future back
10.1016/j.jconrel.2014.03.054 · 2014 · External reference
Inhalable vancomycin-loaded lactose microparticles for treatment of MRSA pneumonia
10.1016/j.jddst.2023.104150 · 2023 · External reference
Improving pulmonary nanotherapeutics using helical aerosol streams: an in silico study
2021 · External reference
Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes
2018 · External reference
Unresolved reference
2007 · External reference
Consequences of chemical impact of disinfectants: safe preventive measures against COVID-19
10.1080/10408444.2020.1790499 · 2020 · External reference
Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020
10.15585/mmwr.mm6912e2 · 2020 · External reference
Just breathe: a review of sex and gender in chronic lung disease
10.1183/16000617.0111-2021 · 2022 · External reference
Unresolved reference
2012 · External reference
Global tuberculosis control: WHO report 2001
2001 · External reference
Particulate and vesicular drug carriers in the management of tuberculosis
10.2174/156720106775197448 · 2006 · External reference
New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery
10.1016/j.addr.2009.11.023 · 2010 · External reference
Antitubercular inhaled therapy: opportunities, progress and challenges
10.1093/jac/dki027 · 2005 · External reference
Killer respiratory tract infections: time to turn the tide
10.1097/mcp.0b013e328351f7d8 · 2012 · External reference
Pneumonia in the intensive care unit
10.1097/01.ccm.0000089928.84326.d2 · 2003 · External reference
An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients
10.1164/rccm.2008-740st · 2011 · External reference
Amphotericin B: side effects and toxicity
10.1016/j.riam.2009.06.003 · 2009 · External reference
Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages
10.1016/j.ijpharm.2005.02.003 · 2005 · External reference
Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters
10.1080/10611860290007513 · 2002 · External reference
Respiratory viral infections in patients with chronic, obstructive pulmonary disease
10.1016/j.jinf.2004.07.011 · 2005 · External reference
Viral respiratory tract infections and asthma: the course ahead
10.1016/j.jaci.2010.04.002 · 2010 · External reference
Cancer progress and priorities: lung cancer
10.1158/1055-9965.epi-19-0221 · 2019 · External reference
Epidemiology of lung cancer
2021 · External reference
Lung cancer 2020: epidemiology, etiology, and prevention
10.1016/j.ccm.2019.10.001 · 2020 · External reference
Recent reviews on dendrimers as an immunotherapy-based nanosystem for the effective treatment of cancer
10.2174/2210303112666220422102459 · 2022 · External reference
Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery
10.1016/j.drudis.2019.09.023 · 2020 · External reference
A review on polysaccharides mediated electrospun nanofibers for diabetic wound healing: their current status with regulatory perspective
2023 · External reference
Recent advances in controlled pulmonary drug delivery
10.1016/j.drudis.2014.09.020 · 2015 · External reference
Application of chitosan and its derivatives in medical materials
2023 · External reference
An updated account on formulations and strategies for the treatment of burn infection-A review
10.2174/1381612828666220519145859 · 2022 · External reference
Application of functionalized chitosan in food: a review
2023 · External reference
Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid
10.3109/02652048.2011.599437 · 2011 · External reference
Alginate and hybrid alginate-hyaluronic acid aerogel microspheres as potential carrier for pulmonary drug delivery
10.1016/j.supflu.2019.04.013 · 2019 · External reference
Controlled drug delivery to the lung: influence of hyaluronic acid solution conformation on its adsorption to hydrophobic drug particles
10.1016/j.ijpharm.2006.11.066 · 2007 · External reference
Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs
10.1016/s0168-3659(03)00263-3 · 2003 · External reference
PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application
10.1080/10717544.2021.1938756 · 2021 · External reference
Recent advances in the formulation of PLGA microparticles for controlled drug delivery
10.1007/s40204-020-00139-y · 2020 · External reference
Gastrointestinal uptake of biodegradable microparticles: effect of particle size
10.1023/a:1016085108889 · 1996 · External reference
Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
10.1093/rb/rbac099 · 2023 · External reference
Nano-platform strategies of herbal components for the management of rheumatoid arthritis: a review on the battle for next-generation formulations
2023 · External reference
Novel drug delivery system
2023 · External reference
Derivatization, an applicable asset for conventional HPLC systems without MS detection in food and miscellaneous analysis
2022 · External reference
Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases
10.1007/s13346-019-00690-7 · 2020 · External reference
Therapeutic potential of nanocarrier-mediated delivery of phytoconstituents for wound healing: their current status and future perspective
10.1208/s12249-023-02616-6 · 2023 · External reference
Novel formulation approaches used for the management of osteoarthritis: a recent review
10.2174/1567201819666220901092832 · 2023 · External reference
Preparation and evaluation of PLGA microparticles as carrier for the pulmonary delivery of rhIL-2: I Effects of some formulation parameters on microparticle characteristics
10.3109/02652048.2011.599438 · 2011 · External reference
Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery
10.1016/j.ijpharm.2011.05.007 · 2011 · External reference
Concepts on smart nano-based drug delivery system
10.2174/1872210515666210120113738 · 2022 · External reference
Ideal particle sizes for inhaled steroids targeting vocal granulomas: preliminary study using computational fluid dynamics
10.1177/0194599817742126 · 2018 · External reference
A. 1 S. Group, Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial
10.2337/dc15-0075 · 2015 · External reference
Engineered PLGA nano-and micro-carriers for pulmonary delivery: challenges and promises
10.1111/j.2042-7158.2012.01486.x · 2012 · External reference
Detection of microRNAs in CD34+ microparticles of cord blood units
10.1182/blood.v128.22.820.820 · 2016 · External reference
A drift on liposomes to proliposomes: recent advances and promising approaches
10.1080/08982104.2021.2019762 · 2022 · External reference
Carrier effect in development of rifampin loaded proliposome for pulmonary delivery: a quality by design study
2022 · External reference
Isoniazid proliposome powders for inhalation—preparation, characterization and cell culture studies
10.3390/ijms12074414 · 2011 · External reference
Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach
10.1016/j.pupt.2013.07.006 · 2014 · External reference
Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs)
10.1208/s12249-012-9822-3 · 2012 · External reference
Precision polymer particles by flash nanoprecipitation and microfluidic droplet extraction
10.1021/acsapm.1c00546 · 2021 · External reference
A parenteral docetaxel-loaded lipid microsphere with decreased 7-epidocetaxel conversion in vitro and in vivo
10.1016/j.ejps.2017.09.022 · 2017 · External reference
Inhalable polymeric nano-particulate powders for respiratory delivery
2021 · External reference
Preparation and crystal modification of ibuprofen-loaded solid lipid microparticles
10.1016/s1004-9541(06)60107-9 · 2006 · External reference
Preparation and in vitro evaluation of indomethacin loaded solid lipid microparticles
2009 · External reference
Sustained-release diclofenac potassium-loaded solid lipid microparticle based on solidified reverse micellar solution: in vitro and in vivo evaluation
10.3109/02652048.2012.726284 · 2013 · External reference
Testosterone solid lipid microparticles for transdermal drug delivery Formulation and physicochemical characterization
10.1080/02652040701368865 · 2007 · External reference
Solid lipid microparticles as a sustained release system for pulmonary drug delivery
10.1016/j.ejpb.2006.07.006 · 2007 · External reference
Recent advancements and applications of inhalable microparticles based drug delivery systems in respiratory disorders
2021 · External reference
Endothelial cells grown on thin polyelectrolyte mutlilayered films: an evaluation of a new versatile surface modification
10.1016/s0142-9612(03)00214-x · 2003 · External reference
Endothelial cell—interactions with polyelectrolyte multilayer films
10.1016/j.biomaterials.2004.11.036 · 2005 · External reference
Surface elasticity and charge concentration-dependent endothelial cell attachment to copolymer polyelectrolyte hydrogel
10.1016/j.actbio.2008.07.033 · 2009 · External reference
Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics
10.1021/mp900215p · 2009 · External reference
Nano-inside-micro: disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung
10.1016/j.jconrel.2012.07.026 · 2012 · External reference
Swellable microparticles as carriers for sustained pulmonary drug delivery
10.1002/jps.22003 · 2010 · External reference
Advancements in dry powder delivery to the lung
10.1080/03639040802235902 · 2008 · External reference
Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles
10.1021/mp200351y · 2012 · External reference
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation
10.1016/j.ejpb.2005.05.009 · 2006 · External reference
Effect of particle shape on the tensile strengths of powders
10.1016/0032-5910(85)80066-8 · 1985 · External reference
Unresolved reference
2015 · External reference
The relationship between particle size and solubility
10.1016/0378-5173(92)90184-4 · 1992 · External reference
A recent review on bio-availability enhancement of poorly water-soluble drugs by using bioenhancer and nanoparticulate drug delivery system
10.2174/1381612829666221021152354 · 2022 · External reference
Strategies to address low drug solubility in discovery and development
10.1124/pr.112.005660 · 2013 · External reference
Mesoporous silica nanoparticles for pulmonary drug delivery
10.1016/j.addr.2021.113953 · 2021 · External reference
Evaluating UiO-66 metal–organic framework nanoparticles as acid-sensitive carriers for pulmonary drug delivery applications
10.1021/acsami.0c10900 · 2020 · External reference
Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections
10.1007/s13346-021-00954-1 · 2021 · External reference
Low molecular weight chitosan-coated PLGA nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis
10.3390/ph11010028 · 2018 · External reference
Breaking the in vitro barrier in respiratory medicine Engineered microphysiological systems for chronic obstructive pulmonary disease and beyond
10.1164/rccm.201709-1795pp · 2018 · External reference
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection
10.1128/aac.00872-08 · 2009 · External reference
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections
10.1093/jac/dkn059 · 2008 · External reference
A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers
10.1089/jamp.2008.0693 · 2009 · External reference
Drug delivery for tuberculosis: is inhaled therapy the key to success?
10.4155/tde-2017-0050 · 2017 · External reference
Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT) A prospective, open-label, randomized study
10.1164/rccm.201807-1318oc · 2018 · External reference
The Lord of the Lungs: the essential role of pulmonary surfactant upon inhalation of nanoparticles
10.1016/j.ejpb.2019.09.020 · 2019 · External reference
Nanocarriers as drug delivery system
2019 · External reference
Nanotechnology from particle size reduction to enhancing aqueous solubility
2016 · External reference
Polymeric nanoparticles in hybrid catalytic processing and drug delivery system
2022 · External reference
A recent update: solid lipid nanoparticles for effective drug delivery
2022 · External reference
Liposomal andrographolide dry powder inhalers for treatment of bacterial pneumonia via anti-inflammatory pathway
10.1016/j.ijpharm.2017.06.005 · 2017 · External reference
Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers
10.1016/j.jconrel.2010.02.006 · 2010 · External reference
A detailed discussion on interpenetrating polymer network (IPN) based drug delivery system for the advancement of health care system
2022 · External reference
Solid lipid nanoparticles
2006 · External reference
Solid lipid nanoparticles
10.3390/encyclopedia2020063 · 2022 · External reference
Novel approaches of solid lipid nanoparticles as drug carrier
10.1002/9783527832095.ch5 · 2022 · External reference
Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles
10.2147/ijn.s30428 · 2012 · External reference
Inhaled nano-and microparticles for drug delivery
10.5339/gcsp.2015.2 · 2015 · External reference
Foam-based drug delivery: a newer approach for pharmaceutical dosage form
10.1208/s12249-022-02390-x · 2022 · External reference
Inhaled antibiotics for mycobacterial lung disease
10.3390/pharmaceutics11070352 · 2019 · External reference
Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation
10.1016/j.ijpharm.2019.05.068 · 2019 · External reference
Effective treatment of Mycobacterium avium subsp hominissuis and Mycobacterium abscessus species infections in macrophages, biofilm, and mice by using liposomal ciprofloxacin
10.1128/aac.00440-18 · 2018 · External reference
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
10.1136/thoraxjnl-2013-203207 · 2013 · External reference
Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis
10.1164/rccm.201203-0487oc · 2012 · External reference
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
10.1016/s2213-2600(18)30427-2 · 2019 · External reference
Regional lung deposition and clearance of 99 mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma
10.1378/chest.113.6.1573 · 1998 · External reference
Pulmonary pharmacokinetics of cyclosporin A liposomes
10.1016/s0378-5173(97)00351-7 · 1998 · External reference
A dry powder formulation of liposome-encapsulated recombinant secretory leukocyte protease inhibitor (rSLPI) for inhalation: preparation and characterisation
10.1208/s12249-010-9500-2 · 2010 · External reference
Surface engineering of liposomes for stealth behavior
10.3390/pharmaceutics5040542 · 2013 · External reference
Terminology for biorelated polymers and applications (IUPAC Recommendations 2012)
10.1351/pac-rec-10-12-04 · 2012 · External reference
Polymeric micelles for pulmonary drug delivery: a comprehensive review
10.1007/s10853-020-05361-4 · 2021 · External reference
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
10.1016/j.ijpharm.2012.08.042 · 2013 · External reference
Preparation and characterization of spray-dried inhalable powders containing polymeric micelles for pulmonary delivery of paclitaxel in lung cancer
2018 · External reference
Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate
10.1166/jnn.2006.426 · 2006 · External reference
Dendrimers for pulmonary delivery: current perspectives and future challenges
10.1039/c9nj01591d · 2019 · External reference
Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature
10.1021/nl5048972 · 2015 · External reference
Unresolved reference
2001 · External reference
PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization
10.1016/j.ijpharm.2013.11.023 · 2014 · External reference
Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention
2014 · External reference
Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers
10.1016/j.ejpb.2017.07.005 · 2017 · External reference
Nanocrystal technology, drug delivery and clinical applications
2008 · External reference
Drug nanocrystals: four basic prerequisites for formulation development and scale-up
10.2174/1389450115666141120114036 · 2015 · External reference
Drug nanocrystals: a way toward scale-up
10.1016/j.jsps.2014.04.007 · 2016 · External reference
Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy
10.1080/17425247.2020.1798401 · 2020 · External reference
Drug-loaded polymeric nanoparticles: a review
10.1080/00914037.2020.1798436 · 2022 · External reference
Design of polymeric nanoparticles for biomedical delivery applications
10.1039/c2cs15327k · 2012 · External reference
Polymers used in the designing of controlled drug delivery system
10.5958/0974-360x.2017.00168.8 · 2017 · External reference
Polysaccharide hydrogels for modified release formulations
10.1016/j.jconrel.2007.01.004 · 2007 · External reference
Poly (lactic acid)/poly (lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery
10.1007/s40005-019-00443-1 · 2019 · External reference
Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies
10.3390/jfb10010004 · 2019 · External reference
Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles
10.1016/j.ijpharm.2013.02.035 · 2013 · External reference
Lung cancer oncotherapy through novel modalities: gas plasma and nanoparticle technologies
2020 · External reference
Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies
10.1021/acs.chemrev.5b00589 · 2016 · External reference
Poly-(lactic-co-glycolic) acid nanoparticles for synergistic delivery of epirubicin and paclitaxel to human lung cancer cells
10.3390/molecules25184243 · 2020 · External reference
Paclitaxel-loaded poly (glycolide-co-ε-caprolactone)-bD-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy
2013 · External reference
Slow release formulations of inhaled rifampin
10.1208/s12248-008-9044-5 · 2008 · External reference
Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers
10.1016/j.jconrel.2011.08.010 · 2012 · External reference
Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA
10.1016/j.jconrel.2011.08.011 · 2012 · External reference
Unresolved reference
2012 · External reference
Surface Layer modification of poly (d, l-lactic-co-glycolic acid) nanoparticles with targeting peptide: a convenient synthetic route for Pluronic F127–Tuftsin conjugate
10.1021/acs.bioconjchem.8b00156 · 2018 · External reference
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
10.1016/j.addr.2008.11.002 · 2009 · External reference
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier
10.1073/pnas.0905998106 · 2009 · External reference
Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery
10.1002/adma.201201800 · 2012 · External reference
Controlled surface modification with poly (ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus
10.1021/mp8001254 · 2009 · External reference
The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles
10.1016/j.biomaterials.2008.12.076 · 2009 · External reference
Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier
10.1002/ange.200803526 · 2008 · External reference
Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy
10.2217/nnm.12.129 · 2013 · External reference
Mucus as a barrier to lipophilic drugs
10.1016/j.ijpharm.2013.05.040 · 2013 · External reference
Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms
10.1371/journal.pone.0079220 · 2013 · External reference
Using supercritical fluid technology as a green alternative during the preparation of drug delivery systems
10.3390/pharmaceutics11120629 · 2019 · External reference
Design of aerogels, cryogels and xerogels of alginate: effect of molecular weight, gelation conditions and drying method on particles' micromeritics
10.3390/molecules24061049 · 2019 · External reference
Drying using supercritical fluid technology as a potential method for preparation of chitosan aerogel microparticles
10.1208/s12249-015-0312-2 · 2015 · External reference
The position of inhaled chemotherapy in the care of patients with lung tumors: clinical feasibility and indications according to recent pharmaceutical progresses
10.3390/cancers11030329 · 2019 · External reference
Development, in vitro characterization, and in vivo toxicity evaluation of chitosan-alginate nanoporous carriers loaded with cisplatin for lung cancer treatment
10.1208/s12249-020-01735-8 · 2020 · External reference
Animal communication: when i'm calling you, will you answer too?
10.1016/j.cub.2017.05.064 · 2017 · External reference
An exploration of the follow-up up needs of patients with inflammatory bowel disease
10.1016/j.crohns.2013.03.001 · 2013 · External reference
Inkjet dispensing technologies: recent advances for novel drug discovery
10.1080/17460441.2019.1567489 · 2019 · External reference
Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations
10.1002/jps.23522 · 2013 · External reference
Development and optimization of solid lipid nanoparticles of amikacin by central composite design
10.3109/08982100903103904 · 2010 · External reference
Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: in vitro and in vivo evaluation
10.1016/j.ijpharm.2016.11.047 · 2017 · External reference
Thermodynamic, spatial and methodological considerations for the manufacturing of therapeutic polymer nanoparticles
2020 · External reference
Development of a biodegradable nanoparticle platform for sildenafil: formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters
10.1016/j.jconrel.2011.09.058 · 2012 · External reference
Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design
2015 · External reference
Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases
10.1016/j.ijpharm.2013.04.028 · 2013 · External reference
Preparation and characterization of solid lipid nanoparticles containing silibinin
10.1080/10717540701203034 · 2007 · External reference
Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability
10.1021/mp700086j · 2008 · External reference
The liposomal formulation of doxorubicin
10.1016/s0076-6879(05)91004-5 · 2005 · External reference
Cisplatin-loaded polymeric nanoparticles: characterization and potential exploitation for the treatment of non-small cell lung carcinoma
10.1016/j.actbio.2015.02.009 · 2015 · External reference
Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin
10.1158/1535-7163.mct-06-0089 · 2006 · External reference
Sustained release curcumin loaded solid lipid nanoparticles
10.15171/apb.2016.04 · 2016 · External reference
Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application
10.1016/j.ijpharm.2011.07.040 · 2011 · External reference
Hydrogels: an interesting strategy for smart drug delivery
10.4155/tde.12.142 · 2013 · External reference
Nanogels as pharmaceutical carriers: finite networks of infinite capabilities
10.1002/anie.200900441 · 2009 · External reference
Characterization of Burkholderia cepacia complex from cystic fibrosis patients in China and their chitosan susceptibility
10.1007/s11274-009-0187-z · 2010 · External reference
Antimicrobial effect of chitosan nanoparticles on Streptococcus mutans biofilms
10.1128/aem.02941-10 · 2011 · External reference
Chitosan as antimicrobial agent: applications and mode of action
10.1021/bm034130m · 2003 · External reference
Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale
10.1517/17425247.2011.586334 · 2011 · External reference
Functionalized positive nanoparticles reduce mucin swelling and dispersion
10.1371/journal.pone.0015434 · 2010 · External reference
Mucin binding reduces colistin antimicrobial activity
10.1128/aac.00808-15 · 2015 · External reference
Hyaluronic acid improves “pleasantness” and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis
10.1007/s12325-010-0076-8 · 2010 · External reference
Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial
10.1089/jamp.2012.1034 · 2014 · External reference
Utilizing nanoparticles for improving anti-biofilm effects of azithromycin: a head-to-head comparison of modified hyaluronic acid nanogels and coated poly (lactic-co-glycolic acid) nanoparticles
10.1016/j.jcis.2019.08.006 · 2019 · External reference
Biopolymer nanogels improve antibacterial activity and safety profile of a novel lysine-based α-peptide/β-peptoid peptidomimetic
10.1016/j.ejpb.2018.03.012 · 2018 · External reference
Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery
10.1016/j.ijpharm.2005.09.010 · 2005 · External reference
Delivery of liposomes in dry powder form: aerodynamic dispersion properties
10.1016/j.ejps.2003.09.008 · 2003 · External reference
Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection
10.1016/s0168-3659(03)00358-4 · 2003 · External reference
Unresolved reference
2011 · External reference
The antimicrobial efficacy of sustained release silver–carbene complex-loaded L-tyrosine polyphosphate nanoparticles: characterization, in vitro and in vivo studies
10.1016/j.biomaterials.2009.03.044 · 2009 · External reference
Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats
10.1093/jac/dkg317 · 2003 · External reference
Formulation of rifampicin–cyclodextrin complexes for lung nebulization
10.1016/j.jconrel.2008.04.007 · 2008 · External reference
Chitosan-coated liposomes for delivery to lungs by nebulisation
10.1016/j.colsurfb.2009.01.010 · 2009 · External reference
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages
10.1016/j.ijpharm.2003.08.017 · 2004 · External reference
One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis
10.1016/j.jconrel.2008.11.027 · 2009 · External reference
Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection
10.1016/s0006-2952(02)01346-1 · 2002 · External reference
Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model
10.1007/s11095-006-9904-6 · 2006 · External reference
Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis
10.1016/j.jddst.2022.103690 · 2022 · External reference
Tuberculosis-associated anemia: a narrative review
2022 · External reference
Unresolved reference
2022 · External reference
Treatment of tuberculosis in nano era: recent avenues
10.2174/1573407218666220127085637 · 2022 · External reference
Oral solid lipid nanoparticle-based antitubercular chemotherapy
10.1016/j.tube.2005.08.009 · 2005 · External reference
Inhalable spray dried lipidnanoparticles for the co-delivery of paclitaxel and doxorubicin in lung cancer
2020 · External reference
Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment
10.1016/j.ejpb.2014.09.012 · 2014 · External reference
Co-electrospraying technology as a novel approach for dry powder inhalation formulation of montelukast and budesonide for pulmonary co-delivery
10.1016/j.ijpharm.2020.119970 · 2020 · External reference
Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles
10.1016/j.ejpb.2020.10.010 · 2020 · External reference
Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro
10.2217/nnm-2020-0475 · 2021 · External reference
Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases
10.1016/j.jiac.2020.04.007 · 2020 · External reference
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
10.1016/s2213-2600(21)00160-0 · 2021 · External reference
Pulmonary delivery of hydroxychloroquine nanostructured lipid carrier as a potential treatment of COVID-19
10.3390/polym14132616 · 2022 · External reference
Aerosol inhalation delivery of triazavirin in mice: outlooks for advanced therapy against novel viral infections
10.1016/j.xphs.2020.11.016 · 2021 · External reference
Polymeric nanoparticles in development for treatment of pulmonary infectious diseases
10.1002/wnan.1401 · 2016 · External reference
Pulmonary drug delivery Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications
10.1046/j.1365-2125.2003.01893.x · 2003 · External reference
Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method
10.3390/molecules25204781 · 2020 · External reference
Nanoparticle-mediated pulmonary drug delivery: a review
10.3390/ijms15045852 · 2014 · External reference
Nanoantioxidants: recent trends in antioxidant delivery applications
10.3390/antiox9010024 · 2019 · External reference
10.1186/rr58 · 2001 · Admitted local publication
Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes
10.1080/10611860600834375 · 2006 · External reference
Inhalation drug delivery devices and emerging technologies
10.1517/13543776.13.9.1333 · 2003 · External reference
New liquid aerosol generation devices: systems that force pressurized liquids through nozzles
2002 · External reference
Deagglomeration of dry powder pharmaceutical aerosols
10.1016/s0378-5173(02)00319-8 · 2002 · External reference
Nanotechnology risk perceptions and communication: emerging technologies, emerging challenges
10.1111/j.1539-6924.2011.01738.x · 2011 · External reference
Effect of the size and surface charge of silica nanoparticles on cutaneous toxicity
10.1007/s13273-013-0010-7 · 2013 · External reference
Structural stability and optical properties of nanomaterials with reconstructed surfaces
10.1103/physrevlett.91.157405 · 2003 · External reference
Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment
10.1038/mt.2009.208 · 2010 · External reference
Nanorobotics control design: a collective behavior approach for medicine
10.1109/tnb.2005.850469 · 2005 · External reference
Nanotechnology: scientific challenges and societal benefits and risks
10.1007/s11661-004-0270-x · 2004 · External reference
10.1021/ac061748o
10.1021/ac061748o · 2007 · External reference
Nanomaterial-based delivery of vaccine through nasal route: opportunities, challenges, advantages, and limitations
10.1016/j.jddst.2022.103533 · 2022 · External reference
Factoring-in agglomeration of carbon nanotubes and nanofibers for better prediction of their toxicity versus asbestos, Part
10.1186/1743-8977-9-10 · 2012 · External reference
A brief review on nanotechnology as a challenging field in pharmaceuticals and their regulatory approval
2020 · External reference
Nanosuspensions: a promising drug delivery strategy
2010 · External reference
Effect of ZnO nanoparticles aggregation on the toxicity in RAW 2647 murine macrophage
10.1016/j.jhazmat.2014.01.043 · 2014 · External reference
Giant frictional dissipation peaks and charge-density-wave slips at the NbSe2 surface
10.1038/nmat3836 · 2014 · External reference
Nanocarriers for anticancer drugs: challenges and perspectives
10.1016/j.sjbs.2022.103298 · 2022 · External reference
CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways
10.1183/16000617.0068-2019 · 2020 · External reference
Abundance of non-polarized lung macrophages with poor phagocytic function in chronic obstructive pulmonary disease (COPD)
10.3390/biomedicines8100398 · 2020 · External reference
Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD
10.1183/16000617.0112-2021 · 2022 · External reference
Lung lymphatic anatomy and correlates
10.1016/j.pathophys.2009.10.008 · 2010 · External reference
Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases
10.1016/s0009-2509(03)00234-3 · 2003 · External reference
Investigation of a pMDI system containing chitosan microspheres and P134a
10.1016/s0378-5173(98)00266-x · 1998 · External reference
Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19
10.2217/nnm-2020-0247 · 2020 · External reference
Nanomedicine as a future therapeutic approach for Hepatitis C virus
10.2217/nnm-2018-0348 · 2019 · External reference
Franz diffusion cell and its implication in skin permeation studies
2023 · External reference
Development and in vitro evaluation of linear PEI-shelled heparin/berberine nanoparticles in human osteosarcoma U-2 OS cells
10.3390/molecules23123121 · 2018 · External reference
Binding of chloroquine–conjugated gold nanoparticles with bovine serum albumin
10.1016/j.jcis.2010.12.032 · 2011 · External reference
Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients
10.7150/thno.46691 · 2020 · External reference
Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: a patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion
10.1016/j.ijpharm.2021.121133 · 2021 · External reference
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19, Med
10.1016/j.mehy.2020.110110 · 2020 · External reference
Nebulised isotonic hydroxychloroquine aerosols for potential treatment of COVID-19
10.3390/pharmaceutics13081260 · 2021 · External reference
Rational development of a carrier-free dry powder inhalation formulation for respiratory viral infections via quality by design: a drug-drug cocrystal of favipiravir and theophylline
10.3390/pharmaceutics14020300 · 2022 · External reference
Multifunctional nanocarriers for lung drug delivery
10.3390/nano10020183 · 2020 · External reference
Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices
10.1080/10717544.2021.1981492 · 2021 · External reference
Inhaled nanoparticles–An updated review
10.1016/j.ijpharm.2020.119671 · 2020 · External reference
Nanotechnology in pulmonary medicine
10.1016/j.coph.2020.11.002 · 2021 · External reference
